Prosecution Insights
Prosecution Insights
Tech Center 3900 • Art Units: 1600 1651 1653 3991
This examiner grants 32% of resolved cases
Lora E. Barnhart Driscoll works in Art Unit 1600 within Tech Center 3900. The examiner has 400 resolved cases and an allowance rate of 32.0%. This rate suggests a rigorous examination process. The median days to allowance is 1783, which is a long timeline for successful prosecution.
The interview lift is 20.0%, indicating that direct communication can improve the chances of allowance compared to the 32.0% baseline. Practitioners should be prepared for a long process, given the 1783-day median duration. The 400 resolved cases provide a solid basis for these metrics.
In Tech Center 3900, the 32.0% allowance rate and 20.0% interview lift suggest that a persistent approach is necessary. The 1783-day median timeline is a key factor for planning in Art Unit 1600. These figures offer a data-grounded view of the examiner's history.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19051130 | METHOD OF MANUFACTURING TRANSGLUCOSYLATED STEVIOL GLYCOSIDES USING THE LACTOBACILLUS MALI | Non-Final OA | CJ CHEILJEDANG CORPORATION |
| 18547471 | ANTIBODIES, FRAGMENTS OR DERIVATIVES SPECIFICALLY BINDING TO A PROTEIN ANTIGEN CAPABLE OF BINDING TO NUCLEIC ACIDS AND USES OF SAME | Final Rejection | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES |
| 19312085 | RECOMBINANT ADENOVIRUSES AND USE THEREOF | Non-Final OA | Washington University |
| 18134886 | NANOSCALE PROCESS TO GENERATE REAGENTS SELECTIVE FOR INDIVIDUAL PROTEIN VARIANTS | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18855981 | METHOD OF MEASURING LEVEL OF IMMUNE SUPPRESSION | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 18131746 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS | Non-Final OA | MARY KAY INC. |
| 18778044 | RNA INTERFERENCE COMPOSITIONS AND METHODS FOR MALIGNANT TUMORS | Non-Final OA | Nitto Denko Corporation |
| 19083131 | REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION | Non-Final OA | The Scripps Research Institute |
| 18810305 | REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION | Non-Final OA | The Scripps Research Institute |
| 18774363 | NANOEMULSION COMPOSITIONS OF TAXOID DRUGS, AND METHODS FOR THE USE THEREOF TO TARGET CANCER CELLS AND CANCER STEM CELLS | Final Rejection | Northeastern University |
| 18847735 | Heparanase Inhibition for Graft Protection | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18531662 | NON-VIRAL GENE/CARRIER COMPLEX FOR PREVENTION OR TREATMENT OF ACUTE INFLAMMATORY DISEASE | Final Rejection | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS |
| 18264191 | THERAPEUTIC COMBINATION AND USE THEREOF | Final Rejection | Akeso Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy